Metagenomi to Present at 41^st Annual J.P. Morgan Healthcare Conference

Metageno­mi, a genet­ic med­i­cines com­pa­ny pow­ered by the indus­try-lead­ing port­fo­lio of whol­ly owned, next-gen­er­a­tion gene edit­ing sys­tems, today announced that Bri­an C. Thomas, Ph.D., Chief Exec­u­tive Offi­cer and Founder of Metageno­mi, will present a com­pa­ny overview at 11:00 a.m. PT on Mon­day, Jan­u­ary 9, 2023 at the 41^st Annu­al J.P. Mor­gan Health­care Con­fer­ence being held in San Fran­cis­co, CA.

About Metageno­mi

Metageno­mi is a gene edit­ing com­pa­ny com­mit­ted to devel­op­ing poten­tial­ly cura­tive ther­a­peu­tics by lever­ag­ing a pro­pri­etary tool­box of next-gen­er­a­tion gene edit­ing sys­tems to accu­rate­ly edit DNA where cur­rent tech­nolo­gies can­not. Our metage­nomics-pow­ered dis­cov­ery plat­form and ana­lyt­i­cal exper­tise reveal nov­el cel­lu­lar machin­ery sourced from oth­er­wise unknown organ­isms. We adapt and forge these nat­u­ral­ly evolved sys­tems into pow­er­ful gene edit­ing sys­tems that are ultra-small, extreme­ly effi­cient, high­ly spe­cif­ic and have a decreased risk of immune response. These sys­tems fuel our pipeline of nov­el med­i­cines and can be lever­aged by part­ners. Our goal is to rev­o­lu­tion­ize gene edit­ing for the ben­e­fit of patients around the world. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.